HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 158.73% from the stock’s current price.

A number of other research firms have also recently commented on TLX. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. UBS Group cut their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Telix Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Trading Down 0.4%

TLX opened at $7.73 on Wednesday. The firm’s fifty day moving average is $8.56 and its two-hundred day moving average is $10.46. Telix Pharmaceuticals has a twelve month low of $7.31 and a twelve month high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of large investors have recently bought and sold shares of TLX. Millennium Management LLC bought a new stake in shares of Telix Pharmaceuticals in the third quarter worth $1,883,000. Pier Capital LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth about $1,225,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth about $1,097,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.